HGS pockets $40M for Albuferon, preps Phase III

Human Genome Sciences can bank a $40 million pay check from Novartis, its milestone for a successful Phase IIa trial of Albuferon for chronic hepatitis C. That makes $132.5 million in milestone payments on that single drug program. And HGS is clearly hoping for more--soon. Researchers also announced today that they had wrapped enrollment early for two Phase III trials of Albuferon with data scheduled to arrive in early 2009 and a marketing application later that same year.

- read the release for more information

Related Articles:
Novartis inks major licensing pact with HGS. Report
HGS marks success of Albuferon in IIb. Report
HGS signs $425M deal for BioMed Realty campus. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.